logo
Aldi Food Recall Update: Customers in 37 States Told to 'Discard' Products

Aldi Food Recall Update: Customers in 37 States Told to 'Discard' Products

Newsweek9 hours ago
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources.
Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content.
Major food recalls recently announced by Aldi have impacted shoppers across 37 states, following safety alerts for undeclared allergens and contamination risks.
Aldi, in collaboration with product suppliers and federal authorities, called for the removal and immediate disposal of certain products from shelves to safeguard consumer health.
Notable recalls so far this year include Welby Vitamin B12 due to the presence of an undeclared peanut allergen and several food items, including Casa Mamita Churro Bites and Santa Monica Seafood Atlantic Salmon Portions, prompting advisories for customers to check their pantries and return or discard the affected goods.
FILE - An Aldi supermarket is seen on August 17, 2023 in Pflugerville, Texas.
FILE - An Aldi supermarket is seen on August 17, 2023 in Pflugerville, Texas.Why It Matters
These widespread recalls underscore ongoing challenges in food safety, highlighting the risks that undeclared allergens and microbial contaminants pose to American consumers.
Allergen exposure—even in trace amounts—can trigger severe reactions in susceptible individuals, making prompt recall actions crucial.
Full List of Aldi Food Product Recalls in 2025
Casa Mamita Chicken & Cheese Taquitos
In association with Bestway Sandwiches Inc., Aldi voluntarily recalled Casa Mamita Chicken & Cheese Taquitos due to possible metal contamination. The affected 20-oz boxes (UPC 4061459337471, best by 07/03/25 and 09/25/25) were sold in 31 states. Consumers should discard or return them for a full refund.
Park Street Deli Pork Carnitas
Aldi, in coordination with Cargill Meat Solutions Corp, halted sales of Park Street Deli Pork Carnitas (16 oz trays) on April 21 due to possible metal contamination.
Affected products (UPC 4099100029352, use by 06/30/25 and 07/01/25) were sold in 15 states. Customers should discard or return items for a full refund.
Image of Atlantic Salmon Portions with Seafood Stuffing recalled because it may contain undeclared soy.
Image of Atlantic Salmon Portions with Seafood Stuffing recalled because it may contain undeclared soy.
FDA
Atlantic Salmon Portions with Seafood Stuffing
Manufactured by Santa Monica Seafood, the product was pulled on May 27 after undeclared soy was detected. Impacted Aldi stores were located in California, Nevada, and Arizona. No related illnesses had been reported by the FDA as of the recall date.
Image of Casa Mamita Churro Bites Filled with Chocolate Hazelnut Cream recalled due to potential an undeclared milk allergen.
Image of Casa Mamita Churro Bites Filled with Chocolate Hazelnut Cream recalled due to potential an undeclared milk allergen.
FDA
Casa Mamita Churro Bites Filled with Chocolate Hazelnut Cream
Camerican International issued a voluntary recall on June 4 after identifying undeclared milk in the ingredient list. The product was distributed to Aldi stores in 13 states, including Alabama, Arkansas, Florida, Georgia, Iowa, Illinois, Kentucky, Louisiana, Missouri, Mississippi, North Carolina, South Carolina, and Tennessee. No illnesses were reported at the time of recall.
Welby Vitamin B12
Recalled by RV Pharma on June 13 due to undeclared peanut allergen. Sold at Aldi locations in 37 states. Customers with allergies are advised to avoid consumption and return the product for a full refund.
What People Are Saying
Aldi, in a statement on the recall page of its website, said: "While ALDI is committed to providing only the best quality at the lowest prices, our top priority is the safety of you and your family. From developing stringent standards to working with trusted manufacturers on product quality and testing, every measure possible is taken to fulfill that promise."
Dr. Sebastian Lighvani, director at New York Allergy & Asthma PLLC, previously told Newsweek: "The difference between someone who is allergic and someone who's not, really, at its core is that an allergic individual can come across something as innocuous as a small amount of the food, egg, peanut, milk, and ingest it. And while a normal person will just digest that and process it, an allergic person actually sees this as a foreign threat. And that triggers the allergic response, which can initially be associated with activation of what we think are these antibodies called IgE antibodies that recognize specifically that piece of food, be it protein or egg protein. And that then triggers these cells, called the mast cells, to release all these inflammatory mediators, like histamine and other kinds of mediators, like nutrients, which can have profound effects."
What Happens Next
Consumers who purchased any recalled Aldi products are advised to cease use and discard them immediately or return them to the store for a full refund.
Those who have experienced illness or an allergic reaction after consuming a recalled product should consult a healthcare professional and report incidents to the FDA's MedWatch program.
Ongoing recalls and updates will be posted on Aldi's official newsroom and at government-linked websites.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Ritz Peanut Butter Cracker Recall Sparks Nationwide Warning
Ritz Peanut Butter Cracker Recall Sparks Nationwide Warning

Newsweek

time33 minutes ago

  • Newsweek

Ritz Peanut Butter Cracker Recall Sparks Nationwide Warning

Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Mondelēz Global LLC is recalling multiple carton sizes of Ritz peanut butter cracker sandwiches due to fears the product may be mislabeled. Newsweek reached out to the company via email Tuesday for comment. Why It Matters Numerous recalls have been initiated in 2025 due to the potential of damaged products, foodborne illness, contamination and undeclared food allergens. Millions of Americans experience food sensitivities or allergies every year. According to the Food and Drug Administration (FDA), the nine "major" food allergens in the U.S. are eggs, milk, fish, wheat, soybeans, Crustacean shellfish, sesame, tree nuts and peanuts. People with a sensitivity or allergy to peanuts may experience "serious or life-threatening allergic reactions" if they consume the recalled product, the FDA warns. Accidental ingestion can lead to anaphylaxis, a rapid and life-threatening allergic reaction that requires immediate medical intervention. Even trace amounts of peanuts can cause symptoms from hives and swelling to difficulty breathing and shock. What To Know In the alert, the FDA says the products were manufactured in the United States and sold nationwide. The Ritz Peanut Butter Cracker Sandwiches in eight-pack, 20-pack and 40-pack cartons as well as the 20-pack Ritz Filled Cracker Sandwich Variety Pack cartons are being recalled due to the possibility of the individually wrapped packages inside the carton potentially being labeled cheese, the FDA says. "All outer cartons affected are labeled correctly and provide an allergen advisory statement indicating that the product 'contains peanuts,'" the FDA notes. No other Mondelēz Global LLC products or Ritz products are impacted by the recall. In the alert, the FDA posted a chart with corresponding best if used by dates along with retail UPC numbers. The alert also has pictures of the affected products. Ritz cheese cracker sandwiches, peanut butter cracker sandwiches and Ritz filled cracker sandwich variety packs with different best by dates and UPC numbers are also not affected by the recall. There have been no reported illnesses or injuries as of Tuesday, the alert says. Mondelēz Global LLC reaffirms the recall was initiated as a precaution. A grocery store aisle in Brooklyn is pictured on May 13 in New York City. (Photo by) A grocery store aisle in Brooklyn is pictured on May 13 in New York City. (Photo by) What People Are Saying The FDA in its alert, in part: "The recall was initiated after Mondelēz Global LLC discovered that film packaging rolls used to package individually wrapped products containing peanut butter may contain defects due to a supplier error. Corrective actions are being taken to help ensure this issue does not recur." What Happens Next Customers with questions or concerns may contact the company around the clock via phone at 1-844-366-1171.

Nestlé Is Making a Big Change to Its Products
Nestlé Is Making a Big Change to Its Products

Yahoo

timean hour ago

  • Yahoo

Nestlé Is Making a Big Change to Its Products

Since the beginning of the year, the spotlight has been shining on the ingredients found in our foods—specifically synthetic food dyes. On Jan. 15, the U.S. Food & Drug Administration (FDA) announced its plans to ban Red Dye No. 3. The food additive was determined to violate the Delaney Clause of the Federal Food, Drug, and Cosmetic Act (FD&C Act), which prohibits the use of any food additive that has been found to cause cancer in humans or animals. While Red Dye No. 3 has not been linked to any cancer cases in humans, two studies found that high levels of the additive caused cancer in male lab rats. The FDA declared a deadline for companies to remove Red Dye No. 3 from all products by 2027 to 2028. Since the ruling, all eyes have been on the other six FD&C colors the FDA have deemed safe for food use. In April, the U.S. Department of Health and Human Services (HHS) shared new steps the FDA was taking to remove all petroleum-based synthetic food dyes from all products in the U.S., including the remaining FD&C colors. While not mandatory, the FDA is 'requesting' companies remove Red Dye No. 3 from all products before the deadline, as well as 'working with the industry' to ban FD&C Green No. 3, FD&C Red No. 40, FD&C Yellow No. 5, FD&C Yellow No. 6, FD&C Blue No. 1, and FD&C Blue No. 2 by the end of 2026. Some companies have been proactive in removing the dyes—like Sam's Club, Kraft Heinz, and General Mills. Now, Nestlé is the latest company to announce its plans to remove all FD&C colors from its products. On June 25, Nestlé released a statement declaring plans to 'fully eliminate FD&C colors in its U.S. food and beverage portfolio by mid-2026.' The company stated that it has been working to remove synthetic dyes and 'identify alternative solutions' for over a decade, which has resulted in more than 90% of its products being free of FD&C color additives. Nestlé says it should be 100% synthetic dye-free within the next 12 months. 'As [customers'] diverse dietary preferences and nutritional needs evolve, we evolve with them,' said Marty Thompson, Nestlé USA's CEO, in a press release. Nestlé didn't provide a list of the products that will be changing, but some of its products that still contain synthetic food dyes include select Nesquik milks and some Nestlé Toll House cookie doughs. Nestlé will replace the synthetic FD&C colors with naturally-derived colorants like turmeric, vegetable juice, and annatto extract—similar to what Aldi and Trader Joe's have been using for years. Thompson added that "Nestlé USA remains committed to providing consumers with affordable, high-quality food and beverages.' Read the original article on ALLRECIPES

U.S. FDA Grants Orphan Drug Designation to Adcentrx Therapeutics' ADRX-0405 STEAP1 ADC for Gastric Cancer
U.S. FDA Grants Orphan Drug Designation to Adcentrx Therapeutics' ADRX-0405 STEAP1 ADC for Gastric Cancer

Yahoo

time3 hours ago

  • Yahoo

U.S. FDA Grants Orphan Drug Designation to Adcentrx Therapeutics' ADRX-0405 STEAP1 ADC for Gastric Cancer

Orphan drug designation highlights the potential for ADRX-0405 to address the high unmet need in gastric cancer SAN DIEGO, July 8, 2025 /PRNewswire/ -- Adcentrx Therapeutics ("Adcentrx"), a clinical-stage biotechnology company redefining Antibody-Drug Conjugate (ADC) therapies for cancer treatment and other life-threatening diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to ADRX-0405, for the treatment of patients with gastric cancer. ADRX-0405 is a STEAP1 ADC being evaluated in the Phase 1a portion of an ongoing Phase 1a/b clinical trial (NCT06710379) for the treatment of select advanced solid tumors, including metastatic castration resistant prostate cancer, gastric cancer, and non-small cell lung cancer. While STEAP1 is primarily associated with prostate cancer, there is a meaningful amount of target expression in gastric cancer, making this a potential indication of interest for future clinical development. "Receiving orphan drug designation from FDA is a notable milestone for Adcentrx and reinforces the potential for ADRX-0405 to improve the lives of patients with gastric cancer," said Hui Li, Ph.D., Founder and Chief Executive Officer of Adcentrx. "We are encouraged by the progress of our Phase 1a trial and look forward to further evaluating the safety, tolerability and anti-tumor activity of ADRX-0405 in gastric and other cancers." Gastric cancer, or stomach cancer, is a serious malignancy that develops in the stomach lining and is often diagnosed at advanced stages. The American Cancer Society estimates there will be 30,300 new cases of gastric cancer in the U.S. in 2025, meeting FDA's criteria for a rare disease. The orphan drug designation is a program designed to stimulate the development of treatments for rare diseases, defined as conditions affecting fewer than 200,000 people in the U.S. Benefits of this designation include access to grant funding and scientific assistance, tax credits for qualified clinical trials, waiver of Prescription Drug User Fee Act (PDUFA) application fees, and the potential for seven years of market exclusivity following regulatory approval. About ADRX-0405ADRX-0405 is a clinical-stage next-generation ADC targeting six-transmembrane epithelial antigen of the prostate 1 (STEAP1), a cell surface protein that is upregulated in prostate cancer and certain other cancers with limited expression in normal healthy tissue. The ADC is composed of a humanized IgG1 antibody coupled with a novel topoisomerase inhibitor linker-payload through Adcentrx's innovative i-Conjugation® technology platform – a core component in the design of the company's ADCs. The platform utilizes a cleavable linker and stable conjugation chemistry to enhance payload delivery. This novel technology enables a highly stable ADC with a drug-antibody ratio of eight (DAR 8) to maximize payload delivery to solid tumors. ADRX-0405 preclinical studies have demonstrated its favorable pharmacokinetics, safety profile, and significant efficacy across multiple animal tumor models. ADRX-0405 is currently being evaluated in a Phase 1a/b clinical trial. For more information about the ADRX-0405 Phase 1a/b clinical trial, please refer to the Study ID NCT06710379 on About Adcentrx TherapeuticsAdcentrx is a biotechnology company focused on accelerating breakthroughs in protein conjugate therapeutic development for cancer and other life-threatening diseases. Adcentrx has pioneered the development of an ADC technology platform addressing key components of protein conjugate design to solve challenges typically seen in ADCs. Adcentrx is developing a robust pipeline including two clinical-stage ADCs and multiple preclinical ADCs, all with first-in-class and best-in-class potential. For more information about Adcentrx and its innovative ADC technologies, please visit Contact Information:Investor Relationsir@ View original content to download multimedia: SOURCE Adcentrx Therapeutics

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store